Infectious Disease
GreenLight receives Rwanda FDA approval for Covid-19 mRNA vaccine trial
GreenLight Biosciences has received the Rwanda Food and Drugs Authority (Rwanda FDA) approval for a Phase I/II clinical trial of…
New RSV therapies may accelerate the emergence of resistant strains
Pharmaceutical companies have been working on developing vaccines and other prophylactics for respiratory syncytial virus (RSV) since its discovery in…
Dyadic initiates subject dosing in Phase I trial of Covid-19 booster
Dyadic International has initiated subject dosing in its Phase I clinical trial of the Covid-19 recombinant protein receptor binding domain…
Impact of the COVID-19 pandemic on mental health among people with depression
The COVID-19 pandemic has been ongoing since March 2020, resulting in 609,195,806 confirmed cases and 6,592,280 deaths in the US…
Pipeline Moves: Trial completion bumps advancement prospects for AstraZeneca’s oncology drug
This week on Pipeline Moves, we look at the recent completion of a Phase I/II trial investigating AstraZeneca’s Imfinzi in…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Tevogen Bio reports positive data from Covid-19 T cell therapy trial
Tevogen Bio has reported positive topline data from a clinical trial of off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy TVGN…
Decline in vaccine coverage in US children for second year in a row
Keeping up to date with state-required vaccines in the US—measles, mumps, and rubella vaccine (MMR); diphtheria, tetanus, and acellular pertussis…
New Omicron variant could threaten vulnerable people this winter
Despite high levels of population immunity, the World Health Organization (WHO) has expressed concerns regarding the COVID-19 Omicron variant, XBB.1.5…
Cyrano to initiate Phase II trial of nasal spray therapy for Hyposmia
Cyrano Therapeutics is set to initiate a Phase II clinical trial of its soft mist nasal spray therapy, CYR-064, for…
Shionogi commences Phase I/II/III and Phase III trials of Covid-19 vaccine
Shionogi has commenced Phase I/II/III and Phase III additional dose clinical trials of its vaccine, S-268019, in paediatric subjects in…